S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-3.32%) $1.920
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

Actualizaciones en tiempo real para Bavarian Nordic A/S [BVNRY]

Bolsa: OTC Sector: Healthcare Industria: Biotechnology
Última actualización26 abr 2024 @ 11:20

1.82% $ 7.05

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 11:20):

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name...

Stats
Volumen de hoy 892.00
Volumen promedio 5 243.00
Capitalización de mercado 1.65B
EPS $0 ( 2024-03-07 )
Próxima fecha de ganancias ( $0 ) 2024-05-14
Last Dividend $0.593 ( 2020-03-27 )
Next Dividend $0 ( N/A )
P/E 7.66
ATR14 $0 (0.00%)

Bavarian Nordic A/S Correlación

10 Correlaciones Más Positivas
10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Bavarian Nordic A/S Finanzas

Annual 2023
Ingresos: $7.06B
Beneficio Bruto: $4.52B (64.07 %)
EPS: $19.23
FY 2023
Ingresos: $7.06B
Beneficio Bruto: $4.52B (64.07 %)
EPS: $19.23
FY 2023
Ingresos: $0
Beneficio Bruto: $0 (0.00 %)
EPS: $0
FY 2022
Ingresos: $3.15B
Beneficio Bruto: $1.70B (53.99 %)
EPS: $-4.93

Financial Reports:

No articles found.

Bavarian Nordic A/S Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Bavarian Nordic A/S Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.34 - Potential for dividend initiation, but uncertain (13.19%)
Information
First Dividend $0.593 2020-03-27
Last Dividend $0.593 2020-03-27
Next Dividend $0 N/A
Payout Date 2020-04-06
Next Payout Date N/A
# dividends 1 --
Total Paid Out $0.593 --
Avg. Dividend % Per Year 0.00% --
Score 2.27 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 4.34
Div. Directional Score 7.53 --
Next Divdend (Est)
(2024-04-28)
$0 Estimate 0.00 %
Dividend Stability
0.02 Very Bad
Dividend Score
2.27
Pay Frequency
Insufficient data to determine frequency
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
VTKLY Ex Dividend Knight 2023-07-20 Semi-Annually 0 0.00%
LNVGY Ex Dividend Knight 2023-07-26 Annually 0 0.00%
CKHGY Ex Dividend Knight 2023-05-11 Annually 0 0.00%
SGPYY Ex Dividend Knight 2023-06-01 Semi-Annually 0 0.00%
GMVHY Ex Dividend Junior 2023-08-18 Semi-Annually 0 0.00%
AILLO Ex Dividend Knight 2023-07-14 Semi-Annually 0 0.00%
NACB Ex Dividend Junior 2023-08-15 Quarterly 0 0.00%
CPKF Ex Dividend Knight 2023-08-31 Quarterly 0 0.00%
SZLMY Ex Dividend Junior 2023-05-03 Annually 0 0.00%
HONT Ex Dividend Junior 2023-08-14 Quarterly 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.2091.5005.828.74[0 - 0.5]
returnOnAssetsTTM0.1031.2006.577.89[0 - 0.3]
returnOnEquityTTM0.1531.5009.4110.00[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM1.9380.8005.314.25[1 - 3]
quickRatioTTM1.3420.8006.815.45[0.8 - 2.5]
cashRatioTTM0.5301.5008.1710.00[0.2 - 2]
debtRatioTTM0.00430-1.5009.93-10.00[0 - 0.6]
interestCoverageTTM25.161.0001.7931.793[3 - 30]
operatingCashFlowPerShareTTM14.592.005.1410.00[0 - 30]
freeCashFlowPerShareTTM1.8492.009.0810.00[0 - 20]
debtEquityRatioTTM0.00597-1.5009.98-10.00[0 - 2.5]
grossProfitMarginTTM0.6521.0002.472.47[0.2 - 0.8]
operatingProfitMarginTTM0.2151.0007.707.70[0.1 - 0.6]
cashFlowToDebtRatioTTM18.151.00010.0010.00[0.2 - 2]
assetTurnoverTTM0.4920.800-0.0521-0.0416[0.5 - 2]
Total Score10.72

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM2.551.0009.840[1 - 100]
returnOnEquityTTM0.1532.509.6210.00[0.1 - 1.5]
freeCashFlowPerShareTTM1.8492.009.3810.00[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM14.592.005.1410.00[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM0.002281.500-3.320[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1581.0008.540[0.1 - 0.5]
Total Score4.34

Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Acerca de Señales en Vivo

Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.

Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico